---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-210295"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:56:35.756549+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Climb Bio reports Q1 2026 cash of $146.3M; $110M private placement closed April 29

## Summary
- R&D expense $9.4M vs $17.3M YoY (incl. $9M CLYM116 upfront in prior year); G&A $5.8M.
- Cash, equivalents, and marketable securities $146.3M as of March 31; expects to fund ops into 2028 excluding $110M placement.
- Budoprutug SC formulation showed robust B-cell depletion similar to IV; Phase 2 pMN trial granted FDA Fast Track Designation.
- Initial budoprutug ITP data (low-dose B-cell and platelet) expected June 2026; pMN data Q4 2026.
- CLYM116 nonhuman primate-to-human PK/PD modeling and initial safety data to be presented at ERA June 2026.

## SEC filing metadata
- accession: 0001193125-26-210295
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000119312526210295/0001193125-26-210295-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000119312526210295/clym-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-210295
- JSON: https://secwatch.observer/filing/0001193125-26-210295.json
- Plain text: https://secwatch.observer/filing/0001193125-26-210295.txt

## Key facts
- Earnings Releases
  Climb Bio, Inc. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 7, 2026, Climb Bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768446/000119312526210295/0001193125-26-210295-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.